A Phase III, Randomized, Double-blind, Three-arm, Placebo-controlled, Multi-center Study to Evaluate the Safety and Efficacy of Oral Cladribine in Subjects With Relapsing-remitting Multiple Sclerosis (RRMS)

Trial Profile

A Phase III, Randomized, Double-blind, Three-arm, Placebo-controlled, Multi-center Study to Evaluate the Safety and Efficacy of Oral Cladribine in Subjects With Relapsing-remitting Multiple Sclerosis (RRMS)

Completed
Phase of Trial: Phase III

Latest Information Update: 27 Jun 2017

At a glance

  • Drugs Cladribine (Primary)
  • Indications Multiple sclerosis
  • Focus Registrational; Therapeutic Use
  • Acronyms CLARITY
  • Sponsors EMD Serono; Merck Serono
  • Most Recent Events

    • 27 Jun 2017 Results of an integrated analysis from three studies (ORACLE-MS, CLARITY, and CLARITY Extension) presented at the 3rd Congress of the European Academy of Neurology
    • 27 Jun 2017 Longitudinal (48 weeks) evaluation of peripheral blood lymphocyte subtypes from patients of ORACLE-MS, CLARITY and CLARITY Extension; results presented at the 3rd Congress of the European Academy of Neurology
    • 27 Jun 2017 Results assessing the absolute lymphocyte count in patients treated with cladribine 3.5mg/kg using pooled data (n=685) from CLARITY and CLARITY Extension and PREMIERE registry along with data from patients randomised to placebo (n=435) in CLARITY and followed up in CLARITY Extension and PREMIERE, presented at the 3rd Congress of the European Academy of Neurology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top